


## Amendments to the Claims

1. (currently amended) A compound of Formula (I)



or pharmaceutically acceptable salt or solvate thereof,

wherein

B is CH or N;

D is CH<sub>2</sub> or NH;

R<sup>1</sup> is selected from the group consisting of H, -CN, C<sub>1-4</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy and N(C<sub>1-4</sub> alkyl)<sub>2</sub>, optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C<sub>1-4</sub> haloalkyl and C<sub>1-4</sub> alkoxy;

R<sup>2</sup> is selected from the group consisting of H, halo, -CN, hydroxy, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkyl, -NR<sup>4</sup>R<sup>6</sup>, -C<sub>1-6</sub> alkylNR<sup>4</sup>R<sup>6</sup>, -C<sub>1-6</sub> alkylOR<sup>6</sup>, CO<sub>2</sub>R<sup>6</sup>, O<sub>2</sub>CR<sup>6</sup>, COR<sup>6</sup>, CON<sup>4</sup>R<sup>6</sup>, NR<sup>4</sup>CO<sub>2</sub>R<sup>6</sup>, NR<sup>4</sup>SO<sub>2</sub>R<sup>6</sup>, NR<sup>4</sup>COR<sup>6</sup>, OCONR<sup>4</sup>R<sup>6</sup> and NR<sup>4</sup>CONR<sup>5</sup>R<sup>6</sup>;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting

USSN 10/800,241

CT-2774 NP

of -CN, hydroxy, halo, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, CO<sub>2</sub>C<sub>1-4</sub> alkyl or phenyl; or

R<sup>2</sup> is morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>3-6</sub> cycloalkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl, -CN, SH, -S(O)<sub>2</sub>R<sup>5</sup>, -COR<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -OC(O)R<sup>5</sup>, -N(COR<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>R<sup>7</sup> and -CONR<sup>4</sup>R<sup>7</sup>, -NR<sup>4</sup>COR<sup>5</sup>, NR<sup>4</sup>SO<sub>2</sub>R<sup>5</sup>, NR<sup>4</sup>CONR<sup>5</sup>R<sup>7</sup> or NR<sup>4</sup>CO<sub>2</sub>R<sup>5</sup>;

R<sup>3</sup> is selected from the group consisting of H, halo, -CN, hydroxy, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkyl, -NR<sup>4</sup>R<sup>6</sup>, -C<sub>1-6</sub> alkylNR<sup>4</sup>R<sup>6</sup>, -C<sub>1-6</sub> alkylOR<sup>6</sup>, CO<sub>2</sub>R<sup>6</sup>, O<sub>2</sub>CR<sup>6</sup>, COR<sup>6</sup>, CON<sup>4</sup>R<sup>6</sup>, NR<sup>4</sup>CO<sub>2</sub>R<sup>6</sup>, NR<sup>4</sup>SO<sub>2</sub>R<sup>6</sup>, NR<sup>4</sup>COR<sup>6</sup>, OCONR<sup>4</sup>R<sup>6</sup>, and NR<sup>4</sup>CONR<sup>5</sup>R<sup>6</sup>;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, CO<sub>2</sub>C<sub>1-4</sub> alkyl, phenyl or naphthyl; or

R<sup>3</sup> is morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl,

USSN 10/800,241

CT-2774 NP

pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl, -CN, SH, -S(O)<sub>2</sub>R<sup>5</sup>, -COR<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -OC(O)R<sup>5</sup>, -N(COR<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>R<sup>7</sup> and -CONR<sup>4</sup>R<sup>7</sup>, -NR<sup>4</sup>COR<sup>5</sup>, NR<sup>4</sup>SO<sub>2</sub>R<sup>5</sup>, NR<sup>4</sup>CONR<sup>5</sup>R<sup>7</sup> or NR<sup>4</sup>CO<sub>2</sub>R<sup>5</sup>;

Ar is selected from the group consisting of phenyl, indanyl, indenyl, pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl, -CN, -NO<sub>2</sub>, SH, -S(O)<sub>2</sub>R<sup>5</sup>, -COR<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -OC(O)R<sup>5</sup>, -N(COR<sup>4</sup>)<sub>2</sub>, -NR<sup>4</sup>R<sup>7</sup> and -CONR<sup>4</sup>R<sup>7</sup>, -NR<sup>4</sup>COR<sup>5</sup>, NR<sup>4</sup>SO<sub>2</sub>R<sup>5</sup>, NR<sup>4</sup>CONR<sup>5</sup>R<sup>7</sup>, and NR<sup>4</sup>CO<sub>2</sub>R<sup>5</sup>;

R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are independently selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, C<sub>3-6</sub> cycloalkyl-C<sub>3-6</sub> alkyl, C<sub>1-2</sub> alkoxy-C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl; and

USSN 10/800,241

CT-2774 NP

$R^6$  is selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, C<sub>3-6</sub> cycloalkyl-C<sub>1-6</sub> alkyl, C<sub>1-2</sub> alkoxy-C<sub>1-2</sub> alkyl, C<sub>1-4</sub> haloalkyl, phenyl and C<sub>1-6</sub> alkyl-phenyl.

2. (original) A compound according to claim 1 wherein B is CH.

3. (original) A compound according to claim 1 wherein B is CH and D is CH<sub>2</sub>.

4. (original) A compound according to claim 1 wherein B is CH and D is NH.

5. (original) A compound according to claim 1 wherein R<sup>1</sup> is C<sub>1-4</sub> alkyl.

6. (original) A compound according to claim 1 wherein R<sup>2</sup> is H or substituted or unsubstituted C<sub>1-6</sub>alkyl, morpholinyl, piperazinyl or phenyl.

7. (original) A compound according to claim 1 wherein R<sup>3</sup> is H, halo, CN or hydroxy, substituted or unsubstituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkyl, -NR<sup>4</sup>R<sup>6</sup> or O<sub>2</sub>CR<sup>6</sup>.

8. (original) A compound according to claim 1 wherein R<sup>3</sup> is pyrimidinyl and pyridinyl.

9. (original) A compound according to claim 1 wherein Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl,

USSN 10/800,241

CT-2774 NP

-CN, -NO<sub>2</sub> or -CO<sub>2</sub>R<sup>4</sup>.

10. (original) A compound according to claim 1 wherein R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are independently H or C<sub>1-6</sub> alkyl.

11. (original) A compound according to claim 1 wherein R<sup>6</sup> is H.

12. (original) A compound according to claim 1 wherein R<sup>1</sup> is C<sub>1-4</sub> alkyl; R<sup>2</sup> is H or substituted or unsubstituted C<sub>1-6</sub>alkyl, morpholinyl, piperazinyl or phenyl; R<sup>3</sup> is H, halo, CN or hydroxy, substituted or unsubstituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkyl, -NR<sup>4</sup>R<sup>6</sup> or O<sub>2</sub>CR<sup>6</sup>; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl, -CN, -NO<sub>2</sub> or -CO<sub>2</sub>R<sup>4</sup>; R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are independently H or C<sub>1-6</sub> alkyl; and R<sup>6</sup> is H.

13. (original) A compound according to claim 1 wherein B is CH; R<sup>1</sup> is C<sub>1-4</sub> alkyl; R<sup>2</sup> is H or substituted or unsubstituted C<sub>1-6</sub>alkyl, morpholinyl, piperazinyl or phenyl; R<sup>3</sup> is H, halo, CN or hydroxy, substituted or unsubstituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkyl, -NR<sup>4</sup>R<sup>6</sup> or O<sub>2</sub>CR<sup>6</sup>; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C<sub>1-6</sub> alkyl, -OR<sup>4</sup>, halo, C<sub>1-4</sub> haloalkyl, -CN, -NO<sub>2</sub> or -CO<sub>2</sub>R<sup>4</sup>; R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are independently H or C<sub>1-6</sub> alkyl; and R<sup>6</sup> is H.

14. (original) [5-(4-Methoxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-

USSN 10/800,241

CT-2774 NP

trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenol; Acetic acid 4-[2-methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenyl ester; [5-(4-Benzylxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzylxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(4-methoxy-2-methylphenyl)-amine; [5-(4-Benzylxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(6-methoxy-2-methylpyridin-3-yl)-amine; [5-(3-Benzylxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(3-Benzylxybenzenesulfonyl)-2-methoxypyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 5-(3-Benzylxybenzenesulfonyl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-N<sup>4</sup>-(2,4,6-trimethylphenyl)-pyrimidine-2,4-diamine; {5-[4-(2-Methoxybenzylxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; {5-[4-(3,5-Dimethoxybenzylxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzylxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4-dimethoxyphenyl)-amine; 5-(4-Methoxyoxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; 5-(4-Benzylxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; [5-(4-Fluorobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-morpholin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {2-Methyl-5-[4-(4-methylpiperazin-1-yl)-benzenesulfonyl]-pyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Imidazol-1-yl-benzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrrolidin-1-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzylaminobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {5-[4-(Benzylmethylamino)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-benzonitrile; [2-

USSN 10/800,241

CT-2774 NP

Methyl-5-(toluene-4-sulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-5-yl-benzenesulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-3-yl-benzenesulfonyl)-pyrimidin-4-yl]- (2,4,6-trimethylphenyl)-amine;  
(5-[4-(4,5-Dihydro-1H-imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl)- (2,4,6-trimethylphenyl)-amine; or {5-[4-(1H-Imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl}- (2,4,6-trimethylphenyl)-amine or pharmaceutically acceptable salts or solvates thereof.

15. (currently amended) A pharmaceutical composition comprising of a compound according to claim 1 and a pharmaceutically acceptable carrier.

16. (currently amended) A method of treating depression or anxiety comprising the administration of a compound of claim 15.